Incyte Provides Update on Parsaclisib and MCLA-145

4 years ago

by David Miller

977 Views

Written by David Miller

WILMINGTON, Del.–(BUSINESS WIRE) January 25, 2022 — Incyte (Nasdaq:INCY) today announced updates regarding the clinical development of parsaclisib, the Company’s next-generation oral inhibitor of phosphatidylinositol 3-kinase delta…Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

View all posts

[mwai_chat window="true" fullscreen="true"]

You may also like

About the author

David Miller